Mylan Gets Industry Aid In $50M Tax Fight At 3rd Circ.
By Daniel Ducassi · August 9, 2022, 7:58 PM EDT
A generic-drug manufacturer trade group told the Third Circuit on Monday that taxing patent litigation costs related to the expedited approval process for generic drugs would undermine the purpose of the...
To view the full article, register now.
Try a seven day FREE Trial
Already a subscriber? Click here to login